Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Plant extracts >  Irinotecan hydrochloride

Irinotecan hydrochloride

Basic information Safety Supplier Related

Irinotecan hydrochloride Basic information

Product Name:
Irinotecan hydrochloride
Synonyms:
  • Camptothecin II
  • CPT-II
  • [1,4′-Bipiperidine]-1′-carboxylic acid, CPT-11,(S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl ester
  • (4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl[1,4'-bipiperidine]-1'-carboxylicacidesterhydrochloride
  • (S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl ester
  • Irinotecan hydrochloride(CPT-11)
  • Irinotecan HCI
  • 50MG/200MG/1KG
CAS:
100286-90-6
MF:
C33H39ClN4O6
MW:
623.15
EINECS:
600-054-0
Product Categories:
  • Anti-cancer&immunity
  • Antitumors for Research and Experimental Use
  • Biochemistry
  • Chiral Reagents
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Active Pharmaceutical Ingredients
  • Antineoplastic
  • Pharmaceuticals
  • Irinotecan
  • API
Mol File:
100286-90-6.mol
More
Less

Irinotecan hydrochloride Chemical Properties

Melting point:
250-256°C (dec.)
Boiling point:
257 °C
refractive index 
67.7 ° (C=1, H2O)
storage temp. 
2-8°C
solubility 
Soluble in DMSO or DMF at approximately 20mg/ml. Sparingly soluble in aqueous buffers. /n
Water Solubility 
Soluble in DMSO at 100mg/ml. Soluble in water at 25mg/ml with warming
Merck 
5091
CAS DataBase Reference
100286-90-6(CAS DataBase Reference)
More
Less

Safety Information

Hazard Codes 
Xn
Risk Statements 
22
WGK Germany 
3
RTECS 
DW1060750
HS Code 
29399990
More
Less

Irinotecan hydrochloride Usage And Synthesis

Description

lrinotecan hydrochloride, a semi-synthetic, water soluble derivative of the potent anticancer agent camptothecin, was launched in Japan for the treatment of lung, ovarian, and cervical cancers. lrinotecan exerts its antitumor activity via inhibition of topoisomerase I, a cellular enzyme that is involved in maintaining the topographic structure of DNA during the process of translation, transcription, and mitosis. lrinotecan undergoes de-esterification in vivo to yield an active metabolite, SN-38, which is 1000-fold more potent than the parent. Although being much less toxic than camptothecin, a significant number of patients in clinical trials exhibited side effects of leukopenia, diarrhea, nauseahromiting, and alopecia. Combination therapy of irinotecan with another widely used anticancer agent, cisplatin, has been reported to be superior to either agent alone. lrinotecan is in clinical trials for gastrointestinal, breast, skin, colorectal, pancreatic cancers, mesothelioma and non-Hodgkin's lymphoma.

Chemical Properties

Yellow Crystalline Powder

Originator

Yakult Honsha (Japan)

Uses

antineoplactic;'inhibitor of topoisomerase I

Uses

Irinotecan hydrochloride has been used:
  • in combination with 5-fluorouracil for screening growth inhibitory functionality in MDA-MB-231 breast cancer cells.
  • in chemosensitivity screening of high-grade appendiceal (HGA) and low-grade appendiceal (LGA) organoids.
  • as a chemotherapeutic agent in the cytotoxicity studies in combination with heat shock proteins inhibitors (HPSC1) in HT29 colon cancer cells.

Uses

A DNA topoisomerase inhibitor

Definition

ChEBI: A hydrochloride obtained by combining irinotecan with one molar equivalent of hydrochloric acid. Used (in the form of its trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancr as after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active.

Manufacturing Process

7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin was synthesized by 2 methods.
Method 1.
7-Ethyl-10-hydroxycamptothecin (500 mg, 1.27 mmol) was suspended in dry dioxane (400 ml) and dissolved therein by adding triethylamine (2 ml) to the suspension under warming. This solution was stirred at room temperature while introducing thereinto phosgene prepared toties quoties by decomposing phosgene dimer (trichloromethoxychloroformate, 400 ml) in the presence of an active carbon catalyst. After 0.5 hours, consumption of the starting materials was confirmed and insoluble 10-chlorocarbonyloxy-7- ethylcamptothecin was removed by filtration.
10-Chlorocarbonyloxy-7-ethylcamptothecin (300 mg, 0.66 mmol) is suspended in dry dioxane (50 ml). To this suspension is added 4- piperidinopiperidine (330 mg, 1.96 mmol) as the amine, the reaction followed by the after-treatment was carried out whereby the 7-ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxycamptothecin title compound (154 mg, 39.8%) was obtained.
Method 2.
7-Ethyl-10-hydroxycamptothecin (790 mg, 2.01 mmol) and 1-chlorocarbonyl- 4-piperidinopiperidine (910 mg, 3.95 mmol) were dissolved in anhydrous pyridine (50 ml), and the mixture was stirred for 1 hour at 20°C. The reaction mixture was evaporated to dryness in vacuo, the residue was dissolved in CHCl3 (200 ml). The solution was washed successively with a 7% aqueous solution of NaHCO3 (200 ml), a saturated aqueous solution NaCl, and the CHCl3 layer was filtered, and evaporated in vacuo. The residual material was decolorized by passing it through a short silica gel column. 7-Ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxycamptothecin was obtained as a pale yellow mass, which was recrystallized from ethanol (ca. 60 ml) to give colorless needles (750 mg, 63.5% in yield).
To an ice-cooled suspension in distilled water (15 ml) of 7-ethyl-10-[1-(4- piperidino)piperidino]carbonyloxycamptothecin (1.00 g, 1.7 mmol) was added 0.1 N HCl (15.3 ml, 1.53 mmol), and the suspension was stirred vigorously for 5 minutes under cooling in an ice bath and filtered off. 7-Ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxycamptothecin hydrochloride was obtained in yield 96%.

brand name

Camptosar (Pharmacia &Upjohn) ;Topotecin.

Therapeutic Function

Antineoplastic

General Description

Irinotecan is available in 100-mg or 5-mL vials for IV administrationand is used in combination with 5-FU and leucovorinas first-line treatment of metastatic colon cancer.The agent may also be used as a single agent in colorectalcancer as a second-line therapy when 5-FU therapy hasfailed. Additional uses include small cell lung cancer,NSCLC, cervical cancer, esophageal cancer, and gastric cancer Irinotecan is 30% to 60% plasma protein bound, whereasthe active metabolite SN-38 is 95% protein bound. Bindingof SN-38 as the lactone stabilizes the material to ring opening.The elimination of the agent occurs primarily in the bilewith a minor amount of renal elimination. The excretion ofactive metabolites or inactive metabolites such as the glucuronideSN-38G, which may be converted back to SN-38 inthe bile, has been associated with severe diarrhea. Irinotecanand SN-38 have half-lives of 8 and 14 hours, respectively.Irinotecan has two dose-limiting toxicities, myelosuppressionand diarrhea. The diarrhea occurs in two forms, earlyand late. The early form occurs within the first 24 hours afteradministration. It has been associated with inhibition ofacetylcholinesterase, which results in increased gut motility.This early phase is also associated with flushing, abdominalpain, and excessive sweating. Atropine can be used to relievethese symptoms but it is not recommended for prophylacticuse unless there has been a prior episode. The late-phasediarrhea occurs after 24 hours and has been associated withthe presence of active material, particularly SN-38 in the gut,and may last 3 to 10 days. The prolonged nature may lead todehydration and electrolyte imbalances. Loperamide therapyis recommended at the first appearance of a loose stool. If thediarrhea persists, additional agents may be used includingantibiotics that decrease β-glucosidase–producing bacteria inthe gut and prevent the overgrowth of pathogenic bacteria.111Other toxicities include emesis and alopecia.

Biological Activity

Inhibitor of DNA topoisomerase I that displays antitumor activity against a range of tumor types.

Biochem/physiol Actions

The anticancer agent, irinotecan, is a prodrug that is converted by tissue carboxylesterase to 7-ethyl-10-hydroxycamptothecin (SN-38), a potent inhibitor of DNA topoisomerase I. Its action is terminated by glucuronidation by UDP glucuronosyl transferase 1A1 (UGT1A1). It proves useful in radiation treatment of tumors by sensitizing tissue to radiation damage.

Clinical Use

In combination with fluorouracil, this prodrug camptothecin analogue is considered to be first-line therapy in the treatment of metastatic colorectal cancer. It also has shown efficacy in small cell and nonsmall cell lung cancers when used in combination with cisplatin.

Side effects

Delayed diarrhea induced by irinotecan is dose-limiting and potentially fatal, and vigorous loperamide therapy should be instituted at the first sign of symptoms. Acute diarrhea is attributed to the drug's ability to inhibit acetylcholinesterase and can be addressed through anticholinergic pretreatment. Pretreatment also helps patients to avoid “cholinergic syndrome,” a collection of annoying side effects that include flushing, sweating, blurred vision, lacrimation, and less commonly, bradycardia. Camptothecins also are myelosuppressive, and neutropenia can be severe, particularly in patients with elevated bilirubin levels. Extensive biotransformation also demands cautious use of irinotecan in patients with hepatic dysfunction.

Metabolism

The drug is slowly bioactivated in the liver through hydrolysis of the C10-carbamate ester. The catalyzing enzyme is a saturable carboxylesterase known as irinotecan-converting enzyme. Levels of active metabolite, known as SN-38, are 50- to 100-fold lower than the parent drug, but preferential protein binding of the lactone (95%) permits significant plasma levels of the optimally active SN-38 compared to the hydroxy acid metabolite. SN-38 has a terminal half-life of 11.5 hours (compared to 5.0–9.6 hours for the prodrug parent) and is glucuronidated at the C10 phenol before elimination. CYP3A4 also cleaves the terminal piperidine ring through oxidation at the α-carbons, followed by hydrolysis of the resultant amides, producing inactive metabolites. Excretion of the parent drug and metabolites is renal (14–37%) and, to a lesser extent, biliary.

Irinotecan hydrochlorideSupplier

Shanghai Acebright Pharmaceutical Co.,Ltd. Gold
Tel
021-51323300
Email
daili@acebright.com
Shanghai Boyle Chemical Co., Ltd.
Email
sales@boylechem.com
SiChuang NanBu Honesty Technology Co., Ltd.
Tel
0838-5675166
Email
nbcxkj@126.com
Sichuan Ruibo Technology Co., Ltd
Tel
+86-817-5586080
Email
sales@scrbkj.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801
Email
3bsc@sina.com